{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:48:47Z","timestamp":1786121327263,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.anai.2026.06.017","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:27:15Z","timestamp":1781886435000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting disease activity to predict and prevent damage in obstructive airway diseases"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4288-5973","authenticated-orcid":false,"given":"Ian D.","family":"Pavord","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.anai.2026.06.017_bib0001","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S2213-2600(25)00299-1","article-title":"Reframing remission in severe asthma: a conceptual framework for distinguishing disease activity versus damage","volume":"13","author":"Porsbjerg","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.anai.2026.06.017_bib0002","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/thx.52.6.498","article-title":"The use of induced sputum to investigate airway inflammation","volume":"52","author":"Pavord","year":"1997","journal-title":"Thorax"},{"issue":"5 Pt 1","key":"10.1016\/j.anai.2026.06.017_bib0003","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1164\/ajrccm.158.5.9804028","article-title":"Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis","volume":"158","author":"Pizzichini","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"8651","key":"10.1016\/j.anai.2026.06.017_bib0004","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S0140-6736(89)92801-8","article-title":"Chronic cough: eosinophilic bronchitis without asthma","volume":"1","author":"Gibson","year":"1989","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.anai.2026.06.017_bib0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1136\/thorax.57.10.875","article-title":"Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids","volume":"57","author":"Green","year":"2002","journal-title":"Thorax"},{"issue":"9347","key":"10.1016\/j.anai.2026.06.017_bib0006","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0140-6736(02)11679-5","article-title":"Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial","volume":"360","author":"Green","year":"2002","journal-title":"Lancet"},{"issue":"9171","key":"10.1016\/j.anai.2026.06.017_bib0007","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(99)01813-9","article-title":"Non-eosinophilic corticosteroid unresponsive asthma","volume":"353","author":"Pavord","year":"1999","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.anai.2026.06.017_bib0008","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.anai.2026.06.017_bib0009","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1056\/NEJMoa0805435","article-title":"Mepolizumab for prednisone-dependent asthma with sputum eosinophilia","volume":"360","author":"Nair","year":"2009","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.anai.2026.06.017_bib0010","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.anai.2026.06.017_bib0011","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1164\/rccm.200701-085OC","article-title":"A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma","volume":"176","author":"Flood-Page","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.anai.2026.06.017_bib0012","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.200909-1448OC","article-title":"A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma","volume":"181","author":"Corren","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.anai.2026.06.017_bib0013","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1111\/j.1365-2222.2005.02314.x","article-title":"The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma","volume":"35","author":"Berry","year":"2005","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"10.1016\/j.anai.2026.06.017_bib0014","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","article-title":"Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers","volume":"184","author":"Bafadhel","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.anai.2026.06.017_bib0015","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.202104-1040LE","article-title":"Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant Type 2 signaling in severe asthma","volume":"204","author":"Couillard","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.anai.2026.06.017_bib0016","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/resp.14294","article-title":"Sub-stratification of type 2 high airway disease for therapeutic decision-making: a \u2018bomb\u2019 (blood eosinophils) meets \u2018magnet\u2019 (FeNO) framework","volume":"27","author":"Couillard","year":"2022","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.anai.2026.06.017_bib0017","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S2213-2600(25)00037-2","article-title":"Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials","volume":"13","author":"Meulmeester","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"22","key":"10.1016\/j.anai.2026.06.017_bib0018","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1056\/NEJMoa2021713","article-title":"Phase 2 trial of the DPP-1 inhibitor Brensocatib in bronchiectasis","volume":"383","author":"Chalmers","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.anai.2026.06.017_bib0019","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.anai.2026.06.017_bib0020","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jaci.2008.02.029","article-title":"The inhaled steroid treatment as regular therapy in early asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma","volume":"121","author":"Busse","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2026.06.017_bib0021","doi-asserted-by":"crossref","unstructured":"de Benedictis FM, Beasley R, Pavord I, Szefler SJ, Zar HJ, Bush A. 50 years on: how inhaled corticosteroids have changed the treatment of asthma [e-pub ahead of print]. Lancet Respir Med. doi:10.1016\/S2213-2600(26)00082-2, Accessed April 20, 2026.","DOI":"10.1016\/S2213-2600(26)00082-2"},{"issue":"2","key":"10.1016\/j.anai.2026.06.017_bib0022","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/thoraxjnl-2021-217325","article-title":"Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide","volume":"77","author":"Couillard","year":"2022","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.anai.2026.06.017_bib0023","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jaip.2023.02.042","article-title":"Clinically accessible biomarkers to assess the modifiable risk of asthma\/wheezing attacks in toddlers","volume":"11","author":"Couillard","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.anai.2026.06.017_bib0024","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaci.2023.09.044","article-title":"Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma","volume":"154","author":"Bacharier","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2026.06.017_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.anai.2026.06.017_bib0026","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02536-2017","article-title":"Associations between blood eosinophils and decline in lung function among adults with and without asthma","volume":"51","author":"Hancox","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.anai.2026.06.017_bib0027","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/thorax-2023-220972","article-title":"Type 2 inflammation and lung function decline in chronic airway disease in the general population","volume":"79","author":"\u00c7olak","year":"2024","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.anai.2026.06.017_bib0028","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1164\/rccm.202310-1751LE","article-title":"Biomarkers associated with lung function decline and dupilumab response in patients with asthma","volume":"209","author":"Pavord","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2026.06.017_bib0029","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1183\/13993003.01359-2015","article-title":"Treatable traits: toward precision medicine of chronic airway diseases","volume":"47","author":"Agusti","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2026.06.017_bib0030","unstructured":"Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2014 GINA guidelines. Available at: http:\/\/wwwginasthmaorg\/. Accessed April 20, 2026."},{"issue":"1","key":"10.1016\/j.anai.2026.06.017_bib0031","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type 2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.anai.2026.06.017_bib0032","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.017_bib0033","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S2213-2600(24)00299-6","article-title":"Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial","volume":"13","author":"Ramakrishnan","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.anai.2026.06.017_bib0034","article-title":"Patient pathways for four major chronic respiratory diseases in England between 2008 and 2021","volume":"11","author":"Ioannides","year":"2024","journal-title":"BMJ Open Respir Res"},{"issue":"6","key":"10.1016\/j.anai.2026.06.017_bib0035","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.202401-0023OC","article-title":"Respiratory exacerbations and lung function decline in people with smoking history and normal spirometry","volume":"211","author":"Fortis","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.anai.2026.06.017_bib0036","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/thoraxjnl-2018-212441","article-title":"Measuring lung function in airways diseases: current and emerging techniques","volume":"74","author":"Petousi","year":"2019","journal-title":"Thorax"},{"issue":"14","key":"10.1016\/j.anai.2026.06.017_bib0037","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","article-title":"Global effect of modifiable risk factors on cardiovascular disease and mortality","volume":"389","author":"Magnussen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anai.2026.06.017_bib0038","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068033","article-title":"Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials","volume":"381","author":"H\u00e4ndel","year":"2023","journal-title":"BMJ"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002875?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120626002875?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T03:53:09Z","timestamp":1786074789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120626002875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"alternative-id":["S1081120626002875"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2026.06.017","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting disease activity to predict and prevent damage in obstructive airway diseases","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2026.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}